AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths...

Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...

Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock Adrecizumab, given on top of standard of care, was well tolerated and showed a favorable safety profileAdrecizumab demonstrates a positive trend on survivalAdrenOSS-2 is a biomarker-guided...